Aytu biopharma announces exclusive agreement with fabre-kramer pharmaceuticals to commercialize first-in-class antidepressant exxua(tm) (gepirone) extended-release tablets in the united states

Aytu enters the over $22 billion united states prescription major depressive disorder ("mdd") market with the first-in-class oral selective serotonin 5ht1a receptor agonist for adults with mdd. exxua has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with exxua was comparable to placebo.
AYTU Ratings Summary
AYTU Quant Ranking